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Starch safety in resuscitation
To the Editor: The Western Cape Department of Health (WC 
DoH) has taken a decision to withdraw all intravenous fluids (IVFs) 
containing hydroxyethyl starch (HES) from hospitals in the Western 
Cape,[1] with similar action contemplated in the Free State and 
Gauteng. This was in response to recommendations from:
• The European Medicines Agency’s Pharmacovigilance Risk 
Assessment Committee (EMA PRAC) that HES IVFs be 
withdrawn from clinical use.[2]
• The United Kingdom Medicines and Healthcare Products Regu­
latory Agency (MHRA) which has issued a recall of all HES IVFs 
in the UK.[3]
• The United States Food and Drug Administration[4] which advises 
that HES IVFs be used with caution in ICU, cardiac surgery and 
patients with known kidney disease or coagulopathy. Further 
advice was that HES should be stopped if coagulopathy or renal 
dysfunction develops, as well as that renal function should be 
monitored for 90 days after HES administration.
The actions of the WC DoH could be justified if the 
recommendations from the regulators in Europe, the USA and 
UK were based on relevant scientific evidence. Unfortunately, the 
evidence provided is not only flawed, but also has been applied 
to  clinical scenarios not included in the studies used in evidence. 
Regarding these studies, HES IVFs were administered to critically 
ill patients with sepsis. The oldest study,[5] from 2008, used a 
hyperoncotic (10%) solution of HES 200/0.5 that is no longer 
used in South Africa and differs significantly from the HES IVFs 
currently in use. This caveat applies equally to the recent meta­
analysis of starches in JAMA where the majority of starches used 
were outdated or hyperoncotic or used in unnecessary volumes 
over prolonged periods of time.[6] Subsequent studies include 6S[7] 
from Scandinavia and CHEST[8] from Australasia, which were 
published in 2012.
The 6S[7] trial used a potato­derived 6% (iso­oncotic) HES 130/0.4 
(Venofundin, B Braun) IVF and compared this with Ringer’s acetate 
solution. The study involved 798 patients with an average age of 65. 
Renal replacement therapy (RRT) was used more frequently in the 
HES group (22% v. 16%; p=0.04). However, there was no significant 
difference in the number of patients with a doubling of creatinine 
levels, and only one patient in each group was dialysis­dependent at 
day 90. This finding could be explained by the lack of a protocol for 
RRT. There was a significant difference in 90­day mortality (51% v. 
43%; p=0.03). This study may therefore be summarised as a trial of a 
potato­derived HES IVF v. Ringer’s acetate in an elderly population 
of critically ill septic patients that, although showing a significant 
increase in use of RRT and 90­day mortality, might have been 
influenced by lack of RRT protocols.
The CHEST[8] trial used a waxy maize­derived 6% (iso­oncotic) 
HES 130/0.4 (Voluven, Fresenius­Kabi) IVF compared with 0.9% 
saline. The study involved 6 651 patients with an average age of 63. 
Patients who were included had been admitted to the ICU for more 
than 10 hours and received an average of 3.5 l of other fluids before 
first receiving study fluid. Lactate and base deficit data suggest that 
these patients were already fluid resuscitated on entry to the study. 
The administration of any further volume expander would not 
seem to have been appropriate in these cases. RRT was used more 
frequently in the HES group (7.0% v. 5.8%; p=0.04) but renal injury 
occurred more commonly in the saline group (38.0% v. 34.6%; 
p=0.005). The incidence of renal failure was similar in the two groups, 
at 10.4% and 9.2% respectively (p=0.12), which did not correlate with 
the increased use of RRT in the HES group. An additional problem 
was that, prior to randomisation, HES IVF was given to 509 patients 
in the HES group and 508 patients in the saline group.
Importantly, there was a significant increase in new cardiovascular 
failure in patients receiving saline (39.9% v. 36.5%; p=0.03) but more 
blood products were used in the HES group.
The CHEST trial may be summarised as a trial of HES IVF 
compared with 0.9% saline in an elderly population of critically 
ill, septic patients that showed a significant increase in use of renal 
replacement therapy (but with no difference in mortality at 28 or 90 
days), less renal injury and similar rates of renal failure.
Taken together, the two most recent studies[7,8] indicate, at most, 
that HES is associated with an increased risk of renal replacement 
therapy in elderly, critically ill septic patients. The risk of mortality is 
less clear, with only the 6S study showing an increase in 90­ but not 
28­day mortality, and the substantially larger CHEST study showing 
no difference.
None of the studies used by the regulatory agencies addressed the 
use of HES IVF in patients with trauma or those undergoing major 
elective or emergency surgery for non­septic disease. One of the few 
randomised control trials of HES IVF compared with 0.9% saline 
was undertaken in Cape Town.[9] A total of 109 patients was studied, 
with the 67 patients who suffered penetrating trauma requiring more 
saline (7.4 l v. 5.1 l; p<0.001). Renal injury occurred more frequently 
in the saline group than the HES group (16% v. 0%; p=0.018).
Major trauma or surgery where transfusion is likely is most 
appropriately managed by early administration of blood and blood 
products to maintain oxygen delivery and limit coagulopathy. 
The role of clear fluids, either crystalloid or colloid, is limited 
where transfusion is required.[10] However, a substantial number 
of patients suffering trauma or undergoing elective or emergency 
surgery require intravascular volume replacement but not 
transfusion.
Caesarean section is an example of a procedure requiring volume 
loading owing to spinal anaesthesia and blood loss, where transfusion 
is seldom necessary. A recent meta­analysis has demonstrated the 
efficacy of colloid solutions, including HES IVF for this indication.[11]
Enhanced recovery programmes for major elective surgery, such 
as colectomy, also advocate the use of colloids such as HES IVF for 
replacement of intraoperative blood loss in preference to crystalloids, 
which have a greater potential to cause bowel oedema, leading to ileus 
and anastomotic dehiscence.[12]
Alternatives in such situations (including crystalloids, gelatin 
solutions, blood products such as albumin or plasma) are limited. 
Crystalloids are associated with development of peripheral and 
organ oedema increasing the incidence of abdominal compartment 
syndrome, cardiac and renal failure and exacerbating the acute 
respiratory distress syndrome.[13]
Gelatin solutions are associated with a risk of anaphylaxis and 
have minimal advantages over crystalloids in terms of intravascular 
persistence.[14] Blood products are expensive, are not available in large 
volumes and should only be administered for specific indications.[15]
The authors appeal for a more rational thought process about 
the use of HES IVFs. Owing to possible renal harm in elderly, 
critically ill patients with sepsis, HES IVFs should be withheld from 
them. There is, however, no evidence that HES IVFs should be 
withheld from non­septic patients without critical illness who require 
intravascular volume replacement, but not transfusion. HES IVFs 
for this indication should be retained for use by anaesthesiologists, 
emergency physicians and intensivists.
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To the Editor: The article[1] by Parrish and Blockman in the June 
2013 SAMJ requires a carefully considered, unbiased and scientific 
response, as much of the evidence that relies almost exclusively on 3 
flawed studies is not as strong as these authors would have us believe.
It is profoundly disappointing to see that the authors rely heavily 
on the VISEP study[2] and meta­analyses that include it as evidence 
of starch­associated renal damage. The VISEP study employed 
prolonged infusions of hyperoncotic starch with inadequate 
crystalloid support. It has been known for over 30 years that 
repetitive dosing with hyperoncotic colloids will damage the kidney, 
irrespective of colloid type. Given these conceptual and ethical flaws, 
VISEP, and any meta­analyses that include it, should not be quoted 
as evidence of direct nephrotoxicity or mortality associated with iso­
oncotic tetrastarches.
The CHEST trial[3] to which the authors refer was powered for a 
single endpoint: mortality. The result shows that the starch tested 
in this study does not increase mortality compared with saline. The 
secondary conclusion (that there was an increase in the rate of renal 
replacement therapy) lacks internal validity. After adjustment for 
known covariates, this random observation ceased to be statistically 
significant. No criteria were specified for the initiation of renal 
replacement therapy. RIFLE criteria R and I contradict the finding 
and, in fact, favour HES. The incidence of renal failure, and the 
number of dialysis days (both more robust indicators of renal injury) 
were not different between the groups. The only valid conclusion 
from CHEST is that the HES product used is not associated with 
increased mortality.
In the 6S study,[4] markers of tissue perfusion (lactate, central 
venous oxygen saturation and central venous pressure) were normal 
at study entry, indicating that resuscitation had been completed before 
enrolment.  However, in excess of 4.5l fluid was administered on day 
1, a trend sustained for the next 3 days. Such fluid excess has been 
associated with intensive care mortality and may account for the high 
overall renal injury and mortality reported. These and other criticisms 
have been raised by others in correspondence with the NEJM. It is also 
important to note that the potato­based starch product used in 6S is a 
very different chemical entity from the corn starch­based version.
Exclusion of the initial resuscitation phase in these studies is a fatal 
flaw; repetitive fluid boluses, after initial resuscitation, have been 
shown to be useless and potentially harmful.[5] The only indication 
for the administration of colloids is hypovolaemia, but none of these 
studies demonstrated that the patients were hypovolaemic. The 
administration of colloids in the presence of normal or increased 
plasma volume damages the endothelial glycocalyx, resulting in 
increased transudation into the interstitium.[6] Fluid overload is 
undeniably easier to achieve with inappropriately administered colloid 
than with similar crystalloid volumes. The one incontrovertible fact 
in the fluid debate is that excessive fluid administration is harmful.
A serious weakness of the Parrish and Blockman paper is 
the extrapolation of these intensive care data to other fields of 
resuscitation, particularly those where volume depletion is likely. 
The largest proportion of colloid administration (>80%) is in trauma 
and perioperative settings, yet almost all publications in this area 
have been ignored. Systematic reviews have found no evidence 
whatsoever of renal injury associated with the use of modern HES.[7] 
Recent trauma studies have suggested that the use of colloids in acute 
resuscitation is probably beneficial.[8]
The most significant recent advances in perioperative fluid therapy 
have included crystalloid restriction[9] with reliance on colloid volume 
support against robust markers of volume deficiency. Meta­analysis of the 
use of dynamic monitoring to guide colloid administration clearly showed 
benefit in terms of reduction in complications and hospital stay.[10]
The authors’ article, and recent moves to withdraw HES, have ignored 
the serious criticisms of studies that favour their hypothesis and have 
not considered the peri­operative data that uniformly favour colloid 
use.
In summary, what have we really learned from the recent data? 
The unrestricted use of colloids to treat such nonvolumetric markers 
as central venous pressure, hypotension and inadequate urine output, 
particularly in the later stages of critical illness, is inappropriate 
and potentially harmful, and should be abandoned. Where clear 
markers of hypovolaemia are present, colloids appear to be superior 
to crystalloids for initial resuscitation. There is no evidence of 
harm from any of the modern colloids, including HES (apart from 
anaphylaxis, particularly with the gelatins), when these solutions are 
used for the appropriate indications.
Alternative strategies to the use of synthetic colloids are all 
problematic. Albumin is simply too expensive. Increased use of 
crystalloid for resuscitation has consistently been shown to be 
harmful,[11] with far stronger indicators of harm than those produced 
by Parrish and Blockman. Increased use of blood and blood products 
is equally unsound. Whilst the use of fluids in patients in ICU, and 
in those with sepsis in particular, clearly needs to be re­assessed, 
the perioperative evidence suggests that abandoning HES would do 
substantially more harm than good. Those who advocate this must 
bear the burden of proof that current practice is flawed. There is no 
such evidence in the Parrish and Blockman article.
Space constraints prevent a fuller development of these arguments, 
but all opinions expressed are supported by a full range of references 
that are available on request.
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Parrish and Blockman respond: We are delighted that our article 
has created the opportunity for constructive debate on this topic. Our 
key point was that in the areas where published evidence about HES 
is most robust, there are signals of harm; and these signals are best 
identified by combining information from numerous high­quality 
sources. We also noted that there was insufficient evidence on HES 
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use in other contexts to draw definitive conclusions 
about safety, and that it might be prudent to restrict usage 
until these concerns have been resolved.
Hodgson et al. note the recent international regulatory 
authority activity about HES products. The European 
Medicines Agency’s Pharmacovigilance Risk Assessment 
Committee concluded that the risks of HES products 
outweigh their benefits, and recommended suspending 
their marketing authorisation. The UK’s MHRA has 
withdrawn the products from the market via a Class 2 
Medicines Recall, after the UK Commission on Human 
Medicines concluded that the products’ benefits no 
longer outweigh their risks. The FDA has stated that HES 
solutions should not be used in critically ill adult patients, 
including patients with sepsis and those admitted to the 
ICU, and concluded that a Boxed Warning is warranted. 
A subsequent position statement[1] by UK intensivists, 
anaesthetists and emergency medicine physicians 
supports the use of crystalloids as primary resuscitation 
fluids, in line with the provisional NICE guidelines on 
intravenous fluid therapy.[2]
International regulators do not make such decisions 
lightly, and contrary views need to be backed by 
meticulous reasoning. We are underwhelmed by the 
arguments put forward in the correspondence, and are 
concerned by what at times seems highly selective and in 
some cases simply erroneous interpretations of relatively 
straightforward trial evidence.
The letters from James et al. and Hodgson et al. share 
similar points: that three major trials (VISEP, CHEST 
and 6S), published in internationally respected journals, 
are flawed or lack external validity, and that there is 
sufficient evidence on HES use in other situations to 
pronounce it safer than crystalloid for these indications. 
A third topic concerns choice of alternative fluids and 
was not the focus of our article, but is worth comment.
We note that most of the objections to the three 
trials have been raised previously by industry­affiliated 
commentators, and competently answered in each 
journal’s correspondence section by the particular trial’s 
authors. We see little need to revisit all these issues 
here, but will make the general point that the systematic 
analysis of a body of literature accepts that very few 
trials are devoid of retrospectively identifiable flaws, but 
important trends may still emerge. We are fully aware 
of the issues with VISEP, and mentioned them in the 
article. We did not ‘rely heavily’ on this trial, and in fact 
it was not part of two of the three recent meta­analyses 
demonstrating renal harm. In the third meta­analysis 
(Zarychanski), it contributed 7.6% of the weight of the 
mortality analysis and 18% for renal harm.
Because mortality in CHEST was lower than expected 
(17.5% rather than 26%), even this very large trial was 
effectively underpowered to provide robust efficacy 
evidence on its own, which is where the utility of meta­
analysis becomes apparent. Regarding the assertion that 
CHEST was not powered to assess acute kidney injury, 
we draw attention to the results of the authors’ power 
calculation for acute kidney injury which are provided in 
the statistical methods section of the original paper (90% 
power to detect a 1.5% difference from baseline of 6%, 
with alpha 0.05.) The observation that ‘once adjusted for 
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known covariants this random observation (need for renal replacement 
therapy) ceased to be statistically significant’ is open to alternative 
explanation: the relative risk (RR) for renal replacement therapy 
before adjustment was 1.21 (95% confidence interval (CI) 1.00 ­ 1.45, 
including 1 because of the rounding process); after adjustment, it was 
essentially unchanged (RR 1.20, 95% CI 1.00 ­ 1.44). This is what is 
expected in a large, adequately randomised trial. Overall, the failure to 
demonstrate a mortality advantage (efficacy) in CHEST is precisely our 
point – there is concern about renal harm with no clear countervailing 
benefit on key patient­relevant clinical endpoints.
An error in interpretation of 6S originally made by Wise et al.,[3] 
and corrected in the same NEJM correspondence section by the trial 
authors, has been repeated. Hodgson et al. state: ‘but randomisation 
erred in that more patients receiving HES had septic shock and 
AKI at randomisation (179/336 v. 148/337) and (72/142 vs. 63/140) 
respectively’. The figures come from a pre­defined subgroup analysis 
which showed that, of those patients presenting with shock at 
randomisation, 179 died in the HES group, and 148 in the crystalloid 
group. The two groups were evenly matched, with 84% of both 
groups presenting with shock (336 v. 337 patients.)
The second issue concerns peri­operative/surgical use of HES. James 
et al. refer to two reviews in support of their contention of proven safety; 
both were funded by the product manufacturers, and were the reason 
for our general caveats about interpreting such literature. We remind 
readers that, to be reasonably cautious about interpreting ‘lack of harm’ 
information, very large patient numbers are required for rare outcomes, 
follow­up needs to be for months and not days, and endpoints should 
be patient­relevant and not surrogate physiological markers. While both 
reviews allude to thousands of patients, t the majority in fac are from 
trials where the comparator was another colloid.
Demonstrating that a newer colloid is less dangerous than an older 
one with recognised safety issues is unhelpful when the core issue is 
safety relative to carefully titrated crystalloids. We commented on this 
issue pertaining to the Martin review, and are puzzled by James et al.’s 
insistence on quoting it without addressing our reservations. In the 
published high­quality meta­analyses of HES use in critical illness, the 
numerator (number of events) required to generate a signal of renal 
harm was of the order of 300 ­ 400 in each arm. In the surgical literature, 
numerators are still an order of magnitude lower (appropriate crystalloid 
comparators), and any conclusions about safety must be regarded as 
premature. The same concern applies to other colloids, with a 2012 
systematic review making precisely this point about gelatins.[4]
Both sets of correspondents also argue that HES should still be 
available as there are no appropriate substitutes. HES trials have 
provided powerful signals of renal harm and possible mortality 
concerns in specific clinical contexts. To argue for their ongoing use 
in other contexts where safety information is deficient would only 
make sense if there were clear evidence of important clinical benefits. 
Most of the efficacy evidence put forward by the correspondents is for 
surrogate endpoints, is based on small trials, or involves trial designs 
highly susceptible to bias. The meta­analysis by Li et al.[5] on the use 
of HES as preload in caesarean section patients is a case in point – 
the primary endpoint of hypotension is not defined, in no included 
trial was there a clear description of allocation concealment, and 
the hypotension rate in the control groups varies from 24% to 90%, 
raising concerns about heterogeneity despite the Q statistic. Also, 
in spite of the authors’ contention, the funnel plot may well show 
evidence of publication bias.
In conclusion, we stand by our contention that South African 
clinicians should think carefully when prescribing HES, and we look 
forward to further regulatory guidance from both international bodies 
and the South African MCC on the ongoing use of these products.
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